Low-energy femoral fractures associated with the long-term use of bisphosphonates: A case series from a swiss university hospital

Drug Safety

Volumn 32, Issue 9, 2009, Pages 775-785

  Ing Lorenzini, Kuntheavy ^a,b   Desmeules, Jules ^a,b   Plachta, Olivier ^c   Suva, Domizio ^a,b   Dayer, Pierre ^a,b   Robin, Peter ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Swiss Agency for Therapeutic Products (Swissmedic)   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CORTICOSTEROID; ESOMEPRAZOLE; IBANDRONIC ACID; PAMIDRONIC ACID; PANTOPRAZOLE; PREDNISONE; RABEPRAZOLE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE STRENGTH; CLINICAL ARTICLE; CORTICAL BONE; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; FEMALE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE NONUNION; HUMAN; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STRESS FRACTURE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE NAILS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; SWITZERLAND; TREATMENT OUTCOME;

EID: 68849119205     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-200932090-00002     Document Type: Article

References (45)

1. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008 Jan 23; (1): CD001155
2. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008 Jan 23; (1): CD004523
3. Wells GA, Cranney A, Peterson J, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008 Jan 23; (1): CD003376
4. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007 Mar; 119 Suppl. 2: S150-62
5. Ott SM. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab 2001 Apr; 86 (4): 1835-6
6. Lee P, van der Wall H, Seibel MJ. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007 Jul-Aug; 30 (7): 590-7
7. Cheung RK, Leung KK, Lee KC, et al. Sequential nontraumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007 Dec; 13 (6): 485-9
8. Armamento-Villareal R, Napoli N, Panwar V, et al. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006 Nov 9;355(19): 2048-50
9. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006 Jan; 61 (1): 31-3
10. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005 Mar; 90 (3): 1294-301
11. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007 Mar; 89 (3): 349-53
12. Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008 Feb; 39 (2): 224-31
13. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008 Mar 20;358(12): 1304-6
14. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008 May-Jun; 22 (5): 346-50
15. Kelly WN, Arellano FM, Barnes J, et al., on behalf of the International Society for Pharmacoepidemiology; International Society of Pharmacovigilance. Guidelines for submitting adverse event reports for publication. Drug Saf 2007;30(5): 367-73
16. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002 Jun 1;359(9321): 1929-36
17. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. HORIZON Pivotal Fracture Trial. N Engl J Med 2007 May 3;356(18): 1809-22
18. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348: 1535-41
19. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280: 2077-82
20. Black DM, Reiss TF, Nevitt MC, et al. Design of the Fracture Intervention Trial. Osteoporos Int 1993;3: S29-39
21. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-Term Extension. J Bone Miner Res 2004;19: 1259-69
22. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. FLEX Research Group. JAMA 2006 Dec 27;296(24): 2927-38
23. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in post-menopausal women. Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 2004 Mar 18;350(12): 1189-99
24. Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006 Oct 15;12(20 Pt 2): 6222-30s
25. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007 Nov; 86 (11): 1022-33
26. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009 Jan 1;360(1): 53-62
27. Glowacki J. The deceiving appearances of osteoclasts. N Engl J Med 2009 Jan 1;360(1): 80-2
28. Strewler GJ. Decimal point: osteoporosis therapy at the 10-year mark. N Engl J Med 2004 Mar 18;350(12): 1172-4
29. Ott S. New treatments for brittle bones. Ann Intern Med 2004 Sep 7;141(5): 406-7
30. Carey JJ. What is a "failure" of bisphosphonate therapy for osteoporosis. Cleve Clin J Med 2005 Nov; 72 (11): 1033-9
31. Erviti J, Gorricho J. Use of alendronate after 5 years of treatment [letter]. JAMA 2007 May 9;297(18): 1979
32. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005 Mar; 90 (3): 1897-9
33. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001 May; 28 (5): 524-31
34. Yang KH, Won JH, Yoon HK, et al. High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model. Yonsei Med J 2007 Aug 31;48(4): 653-8
35. Jeal W, Barradell LB, McTavish D. Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs 1997 Mar; 53 (3): 415-34
36. WHO Collaborating Centre for International Drug Monitoring. Caveat document. Accompanying statement to data released from the WHO Collaborating Centre [online]. Available from URL: http://www.who-umc.org/graphics/9510.pdf [Accessed 2009 January 23]
37. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006 Dec 27;296(24): 2947-53
38. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008 Oct; 83 (4): 251-9
39. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008 Aug 12;179(4): 319-26
40. Blank JB, Cawthon PM, Carrion-Petersen ML, et al. Overview of recruitment for the Osteoporotic Fractures in Men Study (MrOS). Contemp Clin Trials 2005;26: 557-68
41. Orwoll E, Blank JB, Barrett-Connor E, et al. Design and baseline characteristics of the Osteoporotic Factures in Men (MrOS) study: a large observational study of the determinants of facture in older men. Contemp Clin Trials 2005;26: 569-85
42. Cummings SR, Nevitt MC, Browner WS, et al. Study of osteoporotic fractures research group: risk factors for hip facture in White women. N Engl J Med 1995;332: 767-73
43. Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ 2008 Aug 12;179(4): 306-7
44. Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13(10): 777-87
45. Strom B. Study designs available for pharmacoepidemiology. In: Strom B, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley & Sons Ltd, 1994: 15-27